Literature DB >> 23247537

The relation between bone and stone formation.

Nancy S Krieger1, David A Bushinsky.   

Abstract

Hypercalciuria is the most common metabolic abnormality found in patients with calcium-containing kidney stones. Patients with hypercalciuria often excrete more calcium than they absorb, indicating a net loss of total-body calcium. The source of this additional urinary calcium is almost certainly the skeleton, the largest repository of calcium in the body. Hypercalciuric stone formers exhibit decreased bone mineral density (BMD), which is correlated with the increase in urine calcium excretion. The decreased BMD also correlates with an increase in markers of bone turnover as well as increased fractures. In humans, it is difficult to determine the cause of the decreased BMD in hypercalciuric stone formers. To study the effect of hypercalciuria on bone, we utilized our genetic hypercalciuric stone-forming (GHS) rats, which were developed through successive inbreeding of the most hypercalciuric Sprague-Dawley rats. GHS rats excrete significantly more urinary calcium than similarly fed controls, and all the GHS rats form kidney stones while control rats do not. The hypercalciuria is due to a systemic dysregulation of calcium homeostasis, with increased intestinal calcium absorption, enhanced bone mineral resorption, and decreased renal tubule calcium reabsorption associated with an increase in vitamin D receptors in all these target tissues. We recently found that GHS rats fed an ample calcium diet have reduced BMD and that their bones are more fracture-prone, indicating an intrinsic disorder of bone not secondary to diet. Using this model, we should better understand the pathogenesis of hypercalciuria and stone formation in humans to ultimately improve the bone health of patients with kidney stones.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23247537      PMCID: PMC3625692          DOI: 10.1007/s00223-012-9686-2

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  89 in total

Review 1.  Genetics of hypercalciuria and calcium nephrolithiasis: from the rare monogenic to the common polygenic forms.

Authors:  Giovanni Gambaro; Giuseppe Vezzoli; Giorgio Casari; Luca Rampoldi; Angela D'Angelo; Loris Borghi
Journal:  Am J Kidney Dis       Date:  2004-12       Impact factor: 8.860

2.  Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. A new characteristic of genetic hypercalciuric stone-forming rats.

Authors:  J Yao; P Kathpalia; D A Bushinsky; M J Favus
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

3.  Determinants of osteopenia in male renal-stone-disease patients with idiopathic hypercalciuria.

Authors:  Emmanuel Letavernier; Olivier Traxer; Michel Daudon; Mohammed Tligui; Jérôme Hubert-Brierre; Dominique Guerrot; Aline Sebag; Laurent Baud; Jean-Philippe Haymann
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-24       Impact factor: 8.237

4.  Increased sensitivity to 1,25(OH)2D3 in bone from genetic hypercalciuric rats.

Authors:  N S Krieger; V M Stathopoulos; D A Bushinsky
Journal:  Am J Physiol       Date:  1996-07

5.  Association of vitamin D receptor-gene (FokI) polymorphism with calcium oxalate nephrolithiasis.

Authors:  Hemant Kumar Bid; Ajay Kumar; Rakesh Kapoor; Rama D Mittal
Journal:  J Endourol       Date:  2005 Jan-Feb       Impact factor: 2.942

6.  Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria.

Authors:  A Ghazali; V Fuentès; C Desaint; P Bataille; A Westeel; M Brazier; L Prin; A Fournier
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

7.  Blood ionized calcium is associated with clustered polymorphisms in the carboxyl-terminal tail of the calcium-sensing receptor.

Authors:  Alfredo Scillitani; Vito Guarnieri; Simona De Geronimo; Lucia Anna Muscarella; Claudia Battista; Leonardo D'Agruma; Francesco Bertoldo; Cinzia Florio; Salvatore Minisola; Geoffrey N Hendy; David E C Cole
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

8.  Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis.

Authors:  M S Pearle; C G Roehrborn; C Y Pak
Journal:  J Endourol       Date:  1999-11       Impact factor: 2.942

9.  Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria.

Authors:  Murray J Favus; Alexander J Karnauskas; Joan H Parks; Fredric L Coe
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

10.  Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone.

Authors:  Melita M Dvorak; Cyrille De Joussineau; D Howard Carter; Trairak Pisitkun; Mark A Knepper; Gerardo Gamba; Paul J Kemp; Daniela Riccardi
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

View more
  7 in total

1.  Stones: Bone health in patients with kidney stones.

Authors:  Miguel Angel Arrabal-Polo; Miguel Arrabal-Martin
Journal:  Nat Rev Urol       Date:  2014-12-09       Impact factor: 14.432

Review 2.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

3.  Increased risk of bone fracture among patients with urinary calculi: a nationwide longitudinal population-based study.

Authors:  S-M Ou; Y-T Chen; C-J Shih; D-C Tarng
Journal:  Osteoporos Int       Date:  2014-12-19       Impact factor: 4.507

4.  The importance of calciuria as lithogenic factors in patients with osteopenia/osteoporosis.

Authors:  Miguel Arrabal-Martin; Antonio Poyatos-Andujar; María del Carmen Cano-García; Miguel Quesada-Charneco; Felix Abad-Menor; María Sierra Girón Prieto; Tomás de Haro Muñoz; Miguel Angel Arrabal-Polo
Journal:  Int Urol Nephrol       Date:  2015-02-05       Impact factor: 2.370

5.  Bone remodeling markers as lithogenic risk factors in patients with osteopenia-osteoporosis.

Authors:  María Sierra Girón-Prieto; Salvador Arias-Santiago; María Del Carmen Cano-García; Antonio Poyatos-Andújar; Tomás de Haro-Muñoz; Felix Abad-Menor; Miguel Quesada-Charneco; Miguel Ángel Arrabal-Polo; Miguel Arrabal-Martín
Journal:  Int Urol Nephrol       Date:  2016-07-04       Impact factor: 2.370

6.  Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study.

Authors:  Donatella Granchi; Renata Caudarella; Claudio Ripamonti; Paolo Spinnato; Alberto Bazzocchi; Annamaria Massa; Nicola Baldini
Journal:  Nutrients       Date:  2018-09-12       Impact factor: 5.717

Review 7.  Role of Citrate in Pathophysiology and Medical Management of Bone Diseases.

Authors:  Donatella Granchi; Nicola Baldini; Fabio Massimo Ulivieri; Renata Caudarella
Journal:  Nutrients       Date:  2019-10-25       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.